Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The short-chain dehydrogenases/reductase DHRS13 suppresses differentiation and mitophagy in glioma cells by modulating retinoic acid signaling and mitochondrial ROS

ABSTRACT: To better understand the complex interplay of undifferentiated cancer cells in tumor malignancy, we have focused on the crucial mechanisms that maintain the undifferentiated state of cancer stem-like cells, which drive tumor growth and therapy resistance. Here, we have identified a protein called dehydrogenase/reductase 13 (DHRS13) abundant in undifferentiated glioblastoma cells. DHRS13 is primarily located in the mitochondria and functions as a retinaldehyde reductase, converting all-trans retinaldehyde to all-trans retinol with a high affinity for NADPH. Remarkably when we deplete DHRS13 from these cells, we observe a significant decrease in tumor initiation and progression. Mechanistically, DHRS13 prevents these cells from differentiating by blocking retinoic acid signaling, thereby maintaining their undifferentiated state. Additionally, depletion of DHRS13 results in mitochondrial reactive oxygen species-driven mitophagy and cell death. These findings hold promise for the development of novel strategies to target undifferentiated cancer cells and potentially leading to improved treatment outcomes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE271448 | GEO | 2024/08/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Profiling of retinaldehyde dehydrogenases in cancer cells

Project description:Retinaldehyde dehydrogenases convert retinal into all-trans retinoic acid (ATRA), thereby regulating cell differentiation and cancer stem cell proliferation. Chemical tools and methods are valuable commodities to study aldehyde dehydrogenase (ALDH) activity in human cells. Here, we describe the design, synthesis and application of LEI-945, a first-in-class activity-based probe modeled on retinal that reports on individual ALDHs in cancer cells. Comparative chemical proteomics with LEI-945 explained the ability of various breast cancer cell lines to produce ATRA via retinaldehyde dehydrogenases isozymes, whereas the ALDEFLUORTM assay could not. Competitive chemical proteomics using LEI-945 revealed that the ALDH inhibitor NCT-505 inhibited both ALDH1A1 and ALDH1A3 in MDA-MB-468 breast cancer cells inducing a cell cycle arrest in the G1 phase as well as cell death through necrosis. Our results show that LEI-945 holds promise to guide the discovery of ALDH-based therapeutics

2019-12-18 | PXD015495 | Pride

Effects of redox modulation by inhibition of Thioredoxin reductase on radiosensitivity and gene expression

Project description:The involvement the thioredoxin system in radiation resistance was investigated in human lung cancer cells by a combination of ionizing radiation and specific thioredoxin reductase-inhibition by a phosphine gold compound. Gene expression profiles (Human Gene 1.0 ST) of lung cancer cells subjected to ionizing radiation and/or inhibition of thioredoxin reductase were studied. Data analyses were performed using the Affymetrix GeneChip Operating Software (GCOS) Version 1.4.

2010-12-03 | E-GEOD-25814 | biostudies-arrayexpress

The short-chain dehydrogenases/reductase DHRS13 suppresses differentiation and mitophagy in glioma cells by modulating retinoic acid signaling and mitochondrial ROS

Project description:The short-chain dehydrogenases/reductase DHRS13 suppresses differentiation and mitophagy in glioma cells by modulating retinoic acid signaling and mitochondrial ROS

| PRJNA1131440 | ENA

Targeting ribonucleotide reductase by 3-AP in primary effusion lymphoma

Project description:KSHV is a principal causative agent of primary effusion lymphoma (PEL) which is lacking of effective treatment. Our previous data have showed that HGF/c-MET pathway is highly active within KSHV+ PEL cells and plays important role in tumor cell survival/growth. By using microarray analysis, we have identified the global gene profile controlled by HGF/c-MET pathway within KSHV+ PEL cell-lines and several novel “druggable” candidates closely related to cancer cell survival/growth, including ribonucleotide reductase (RR). We continue to use microarray analysis to identify the gene profile affected within PEL cells exposure to RR inhibitor, 3-AP.

2018-01-01 | GSE91389 | GEO

Hepatic reductase null

Project description:Microarray analysis to examine the relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (CPR) null mice. Keywords: ordered

2004-07-11 | GSE1468 | GEO

Effects of redox modulation by inhibition of Thioredoxin reductase on radiosensitivity and gene expression

2010-12-03 | GSE25814 | GEO

Development of next-generation retinoid pathway immunotherapeutics through targeting tumor ALDH1a3

Project description:Aldehyde dehydrogenase (ALDH1) activity has long been established as a pro-tumorigenic feature of many cancers, yet the identification of specific isoforms that are enriched in cancer, the mechanism of action of this isoform(s), and viable therapeutic strategies to target this pathway have long remained absent. Whereas one of the well-established functions of the ALDH1a family is the conversion of retinaldehyde into retinoic acid to activate nuclear retinoid signaling, the retinoid pathway is paradoxically hypothesized as a cell-intrinsic tumor suppressor pathway. Here we resolve this long-standing conflict by showing that while ALDH1a3 is broadly overexpressed across diverse cancer types, ALDH1a3 expressing tumor cells often lose the sensitivity to retinoid signaling. Instead, all-trans retinoic acid produced by ALDH1a3 acts in a paracrine fashion to suppress anti-tumor immunity and promote tumor growth. We further used structure-based high throughput screening to develop a series of first-in-class, therapeutically viable antagonists of ALDH1a3 with potent anti-tumor immunotherapeutic activity, an excellent pharmacological profile and no evidence of toxicity. Findings of this study resolve prior contradictions in the retinoid pathway through the development of highly specific and potent ALDH1a3 inhibitors.

2025-08-26 | PXD052693 | Pride

Gene expression signature baesd screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma

Project description:There is a critical need in cancer therapeutics to identify targeted therapies that will improve outcomes and decrease toxicities compared to conventional, cytotoxic chemotherapy. Ewing sarcoma is a highly aggressive bone and soft tissue cancer that is caused by the EWS-FLI1 fusion protein. Although EWS-FLI1 is specific for cancer cells, and required for tumorigenesis, directly targeting this transcription factor has proven challenging. Consequently, targeting unique dependencies or key downstream mediators of EWS-FLI1 represent important alternative strategies. We used gene expression data derived from a genetically defined model of Ewing sarcoma to interrogate the Connectivity Map and identify a class of drugs, iron chelators, that downregulate a significant number of EWS-FLI1 target genes. We then identified ribonucleotide reductase M2 (RRM2), the iron-dependent subunit of ribonucleotide reductase (RNR), as one mediator of iron chelator toxicity in Ewing sarcoma cells. Inhibition of RNR in Ewing sarcoma cells led to apoptosis and cell death in vitro and attenuated tumor growth in vivo in a xenograft model. Additionally, we discovered that the sensitivity of Ewing sarcoma cells to inhibition or suppression of RNR is mediated, in part, by high levels of SLFN11, a protein that sensitizes cells to DNA damage. This work demonstrates a unique dependency of Ewing sarcoma cells on RNR and supports further exploration of clinically used inhibitors of RNR as a therapeutic approach in treating this cancer.

2016-12-01 | GSE79641 | GEO

Quinone reductase 2-dependent HCT116 proteome

Project description:NQO2/QR2 is related to NQO1, a known quionine reductase that functions in detoxicification for cells. NQO2, however, uses a distinct co-substate with uncertain availability in cells and as a result the functions of NQO2 are poorly understood. Here, to gain insight into potential pathways regulated by NQO2, we performed label-free proteomics on isogenic control and NQO2 knockout HCT116 colon cancer cells.

2023-08-15 | PXD033944 | Pride

Azolla leucoanthocyanidin reductase

Project description:Azolla ferns testify: seed plants and ferns share a common ancestor for leucoanthocyanidin reductase enzymes.

| PRJEB39515 | ENA